#United States #Los Angeles #Schall Law Firm #UroGen Pharma #U.S. Securities

UroGen Pharma Ltd. Securities Fraud Class Action

Overview

The Schall Law Firm, a prominent national litigation firm focused on shareholder rights, has announced a class action lawsuit against UroGen Pharma Ltd. (NASDAQ: URGN), alleging significant violations of federal securities laws. Investors who purchased UroGen's stock between July 27, 2023, and May 15, 2025, are particularly encouraged to participate in this legal action as they may be entitled to recover their financial losses.

The Allegations

According to the allegations outlined in the complaint, UroGen Pharma misled investors by providing false information about the effectiveness of its clinical studies, particularly the ENVISION trial for UGN-102. The complaint cites that the study design lacked a necessary concurrent control arm, raising concerns about the validity of the outcomes. Furthermore, the company reportedly disregarded critical warnings from the FDA related to its study methods.

When the true nature of UroGen's clinical studies and the surrounding circumstances came to light, investors’ reactions led to substantial declines in stock value, resulting in significant financial harm for those affected.

How to Take Action

Investors who experienced losses during the class period are urged to reach out to the Schall Law Firm before the deadline of July 28, 2025. Participation in the lawsuit can be initiated by contacting Brian Schall at the firm’s office, located at 2049 Century Park East, Suite 2460, Los Angeles, CA 90067. Furthermore, inquiries can also be made through the firm’s official website or via email at [email protected].

Importance of Class Certification

It is crucial to note that the class has yet to receive certification. Until that process is complete, individuals who do not act may remain unrepresented in this legal matter. For those who wish to assert their rights and potentially recover their losses, taking prompt action is paramount.

About Schall Law Firm

The Schall Law Firm specializes in handling securities class action lawsuits, representing investors worldwide. They are committed to fighting for investor rights and ensuring that justice is served for those impacted by corporate misconduct.

This situation exemplifies the need for vigilance among investors regarding the integrity of corporate statements and the measures taken by management to adhere to regulatory requirements. By being informed and proactive, investors can protect their financial interests effectively.

For investors of UroGen Pharma Ltd., this is an opportunity to seek justice and recovery of losses they may have endured due to the company’s alleged securities fraud.

Conclusion

Investors should explore their options regarding this class action lawsuit seriously and stay informed about developments in the case. As this legal proceeding unfolds, the commitment of shareholders to pursue accountability in the corporate world becomes a pivotal aspect of protecting their investment interests.